Showing results (11-20 of 23) with videos related to
Sort By:
Pageof 3
European Journal of Clinical Pharmacology|January 1, 1990
Multiple dose trial of the thromboxane synthase inhibitor furegrelate in normal subjectsJ S Mohrland, J T Vander Lugt, D B LakingsPharmacology|January 1, 1977
Initial studies on the penetration of spirohydantoin mustard into the cerebrospinal fluid of dogsJ Plowman, D B Lakings, E S Owens, et al.Journal of Pharmaceutical Sciences|September 1, 1979
High-performance liquid chromatographic microdetermination of indoprofen in human milkD B Lakings, C Lizarraga, W J Haggerty, et al.Antimicrobial Agents and Chemotherapy|December 1, 1984
Pharmacokinetics of cefpimizole in normal humans after single- and multiple-dose intravenous infusionsD B Lakings, J M Friis, R J Brown, et al.Journal of Clinical Pharmacology|January 1, 1989
Thromboxane synthase activity and platelet function after furegrelate administration in manJ S Mohrland, J T Vander Lugt, R R Gorman, et al.Antimicrobial Agents and Chemotherapy|February 1, 1986
Pharmacokinetics and dose proportionality of cefpimizole in normal humans after intramuscular administrationD B Lakings, E Novak, J M Friis, et al.Pharmaceutical Research|January 1, 1989
Pharmacokinetics of furegrelate after oral administration to normal humansD B Lakings, J M Friis, C M Lunan, et al.Cancer Research|January 1, 1977
Composition, associated tissue methyltransferase activity, and catabolic end products of transfer RNA from carcinogen-induced hepatoma and normal monkey liversD B Lakings, T P Waalkes, E Borek, et al.Journal of the National Cancer Institute|August 1, 1976
Beta-aminoaciduria in patients with Burkitt's lymphomaT P Waalkes, C W Gehrke, D B Lakings, et al.Cancer Chemotherapy Reports|July 1, 1975
Potential biologic markers in Burkitt's lymphomaT P Waalkes, C W Gehrke, W A Bleyer, et al.Pageof 3